The PRRS Immunology Group at The Pirbright Institute has been awarded an Impact Acceleration Award of £9,000 to progress a novel vaccine for porcine reproductive and
The Vaccine Group is expanding its repertoire of vaccine candidates as it seeks to maximise the potential of its platform herpesvirus gene delivery system. Following the
Most emerging infectious diseases affecting humans in the last century have originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant zoonotic
For the second year running one of TVG’s senior scientists will be presenting the progress we have made on our S. suis vaccine programme. This meeting
Work carried out by TVG and collaborators to isolate and sequence cytomegaloviruses from mastomys rats has been published in the August 2023 Journal of General Virology.
TVG’s CEO Jeremy Salt met with S&P Global Animal Health at the recent VetHealth Global forum on Canada’s Prince Edward Island to discuss plans to fund
TVG’s CEO Jeremy Salt was interviewed recently for the online series ‘Future Biotechnologists’. Read the story here.
Dr Jeremy Salt will be attending the VetHealthGlobal meeting in Prince Edward Island next week. A great opportunity to meet with potential collaborators and investors, alongside
Dr Jeremy Salt, CEO, will be attending BioSeed 2023 on behalf of The Vaccine Group. A great opportunity to talk about TVG and meet up with
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.